Taysha Gene Therapies (TSHA) Stock Price, News & Analysis

Company Overview

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Key Stats

• Today's Range: $2.49 to $2.64
• 50-Day Range: $1.13 to $2.93
• 52-Week Range: $1.05 to $4.17
• Volume: 2.46 million shs
• Average Volume: 3.08 million shs
• Market Capitalization: $545.24 million
• P/E Ratio: 4.03
• Dividend Yield: N/A
• Price Target: $7.57
• Consensus Rating: Buy

Taysha Gene Therapies Stock Analysis - MarketRank™

Taysha Gene Therapies scored higher than 76% of companies evaluated by MarketBeat, and ranked 255th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Taysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Taysha Gene Therapies has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Taysha Gene Therapies are expected to decrease in the coming year, from ($0.35) to ($0.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Taysha Gene Therapies is 4.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.28.

Price to Earnings Ratio vs. Sector

The P/E ratio of Taysha Gene Therapies is 4.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.75.

Price to Book Value per Share Ratio

Taysha Gene Therapies has a P/B Ratio of 6.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.04% of the float of Taysha Gene Therapies has been sold short.

Short Interest Ratio / Days to Cover

Taysha Gene Therapies has a short interest ratio ("days to cover") of 9.4.

Change versus previous month

Short interest in Taysha Gene Therapies has recently increased by 21.88%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Taysha Gene Therapies does not currently pay a dividend.

Dividend Growth

Taysha Gene Therapies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

16.04% of the float of Taysha Gene Therapies has been sold short.

Short Interest Ratio / Days to Cover

Taysha Gene Therapies has a short interest ratio ("days to cover") of 9.4.

Change versus previous month

Short interest in Taysha Gene Therapies has recently increased by 21.88%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.93

News Sentiment

Taysha Gene Therapies has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Taysha Gene Therapies this week, compared to 3 articles on an average week.

Search Interest

13 people have searched for TSHA on MarketBeat in the last 30 days. This is an increase of 86% compared to the previous 30 days.

MarketBeat Follows

3 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Taysha Gene Therapies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,062,500.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 3.78% of the stock of Taysha Gene Therapies is held by insiders.

Percentage Held by Institutions

77.70% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TSHA Stock Analysis - Frequently Asked Questions

How have TSHA shares performed this year?

Taysha Gene Therapies' stock was trading at $1.73 at the beginning of the year. Since then, TSHA shares have increased by 46.8% and is now trading at $2.54.
View the best growth stocks for 2025 here.

How were Taysha Gene Therapies' earnings last quarter?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) released its quarterly earnings results on Thursday, May, 15th. The company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). The company earned $2.30 million during the quarter, compared to analyst estimates of $1.48 million. Taysha Gene Therapies had a negative trailing twelve-month return on equity of 106.36% and a negative net margin of 229.67%.
Read the conference call transcript.

When did Taysha Gene Therapies IPO?

Taysha Gene Therapies (TSHA) raised $125 million in an initial public offering on Thursday, September 24th 2020. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies served as the underwriters for the IPO and Chardan was co-manager.

Who are Taysha Gene Therapies' major shareholders?

Top institutional investors of Taysha Gene Therapies include Octagon Capital Advisors LP (5.22%), Siren L.L.C. (3.18%), Siren L.L.C. (3.18%) and Granahan Investment Management LLC (0.80%). Insiders that own company stock include RA Session II, Paul B Manning, Sean P Nolan, Suyash Prasad, Kamran Alam and Sukumar Nagendran.
View institutional ownership trends.

How do I buy shares of Taysha Gene Therapies?

Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Taysha Gene Therapies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Taysha Gene Therapies investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alphabet (GOOG), Visa (V) and Walt Disney (DIS).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 6/14/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TSHA
• CIK: 1806310
• Web: www.tayshagtx.com
• Phone: 214-612-0000
• Fax: N/A
• Employees: 180
• Year Founded: 2020

Price Target and Rating

• Average Stock Price Target: $7.57
• High Stock Price Target: $11.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +198.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.34)
• Trailing P/E Ratio: 4.03
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$111.57 million
• Net Margins: -229.67%
• Pretax Margin: -229.67%
• Return on Equity: -106.36%
• Return on Assets: -49.16%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 5.51
• Quick Ratio: 5.51

Sales & Book Value

• Annual Sales: $7.22 million
• Price / Sales: 75.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.40 per share
• Price / Book: 6.35

Miscellaneous

• Outstanding Shares: 214,662,000
• Free Float: 199,410,000
• Market Cap: $545.24 million
• Optionable: Optionable
• Beta: 1.04